Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1500||SWOG||A Randomized; Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968]; Crizotinib [NSC #749005]; Savolitinib [NSC #785348]; and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)||Adult CIRB - Late Phase Emphasis||Available to Open|
|AAML0431||COG||The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|10042||ETCTN||A Phase II trial of AZD9291 (osimertinib) with or without bevacizumab in patients with EGFR mutation positive NSCLC and brain metastases||Adult CIRB - Early Phase Emphasis||Available to Open|
|A221504||Alliance||A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer||Cancer Prevention and Control CIRB||Available to Open|
|AGCT1532||COG||Phase 3 Accelerated BEP Trial: A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors||Pediatric CIRB||Available to Open|
|E1912||ECOG||A Randomized Phase III Study of Ibrutinib (PCI- 32765)-based Therapy vs Standard Fludarabine; Cyclophosphamide; and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041701||Alliance||A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|PACCT-1||ECOG||Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACNS1833||COG||A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)||Pediatric CIRB||Available to Open|
|GOG-0261||GOG||A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV; Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus; Fallopian Tube; Peritoneum or Ovary||Adult CIRB - Late Phase Emphasis||Available to Open|